Stock 2552 HUA MEDICINE (SHANGHAI) LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hua Medicine (Shanghai) Ltd.

Equities

2552

KYG4644K1022

Market Closed - Hong Kong S.E.
Other stock markets
 01:39:00 03/05/2024 pm IST 		5-day change 1st Jan Change
1.59 HKD -1.24% Intraday chart for Hua Medicine (Shanghai) Ltd. -1.85% -19.29%
28/03 Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
HUA MEDICINE (SHANGHAI) LTD. Stock Hua Medicine (Shanghai) Ltd.
-19.29% 199M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
B+
ARGENX SE Stock argenx SE
+4.40% 22.94B
B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
B+
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2552 Stock
  4. Ratings Hua Medicine (Shanghai) Ltd.